Literature DB >> 19184023

[Immunohistochemistry in breast pathology: differential diagnosis of epithelial breast lesions].

W Böcker1, D Hungermann, S Weigel, J Tio, T Decker.   

Abstract

Proliferative epithelial breast lesions include a wide variety of benign hyperplastic and noninvasive neoplastic lesions, as well as invasive carcinomas. Mammographically these lesions may show microcalcifications, architectural distortions or mass lesions. The task of the pathologist begins with a preoperative diagnosis by means of minimally invasive biopsy. His diagnosis forms the basis for not only the radiological-pathological correlation diagnosis, but also for the management of benign proliferative breast disease lesions, as well as therapeutic decisions in the case of malignant lesions.In daily practice, immunohistochemistry is the method of choice for clarifying difficult cases. The aim of this chapter is to describe the relevant markers in breast pathology and to provide an algorithmic approach to different proliferative breast disease lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184023     DOI: 10.1007/s00292-008-1103-2

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  22 in total

1.  Estrogen receptor-positive proliferating cells in the normal and precancerous breast.

Authors:  B S Shoker; C Jarvis; R B Clarke; E Anderson; J Hewlett; M P Davies; D R Sibson; J P Sloane
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast.

Authors:  M G Joshi; A K Lee; C A Pedersen; S Schnitt; M G Camus; K S Hughes
Journal:  Mod Pathol       Date:  1996-01       Impact factor: 7.842

3.  Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells.

Authors:  R B Nagle; W Böcker; J R Davis; H W Heid; M Kaufmann; D O Lucas; E D Jarasch
Journal:  J Histochem Cytochem       Date:  1986-07       Impact factor: 2.479

4.  Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast.

Authors:  U Raju; J D Crissman; R J Zarbo; C Gottlieb
Journal:  Am J Surg Pathol       Date:  1990-10       Impact factor: 6.394

5.  Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis.

Authors:  F Moinfar; Y G Man; L Arnould; G L Bratthauer; M Ratschek; F A Tavassoli
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

6.  Oestrogen receptor expression in the normal and pre-cancerous breast.

Authors:  B S Shoker; C Jarvis; D R Sibson; C Walker; J P Sloane
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

7.  Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.

Authors:  Magali Lacroix-Triki; Eliane Mery; Jean-Jacques Voigt; Luc Istier; Philippe Rochaix
Journal:  Virchows Arch       Date:  2003-04-24       Impact factor: 4.064

8.  Tubular adenosis of the breast. A distinctive benign lesion mimicking invasive carcinoma.

Authors:  K C Lee; J K Chan; E Gwi
Journal:  Am J Surg Pathol       Date:  1996-01       Impact factor: 6.394

9.  Is microglandular adenosis a precancerous disease? A study of carcinoma arising therein.

Authors:  M K Rosenblum; R Purrazzella; P P Rosen
Journal:  Am J Surg Pathol       Date:  1986-04       Impact factor: 6.394

10.  Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept.

Authors:  Werner Böcker; Roland Moll; Christopher Poremba; Roland Holland; Paul J Van Diest; Peter Dervan; Horst Bürger; Daniel Wai; Raihanatou Ina Diallo; Burkhard Brandt; Hermann Herbst; Ansgar Schmidt; Markus M Lerch; Igor B Buchwallow
Journal:  Lab Invest       Date:  2002-06       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.